Itau Unibanco Holding S.A. Decreases Stake in Pfizer Inc. $PFE

Key Points

• Itau Unibanco Holding S.A. significantly reduced its stake in Pfizer Inc. by 99.7% in the first quarter, now holding only 1,720 shares after selling 500,000 shares during the period.
• Several institutional investors, including Brighton Jones LLC, have increased their positions in Pfizer, with Brighton boosting its stake by 1,282.4% in the last quarter.
• Pfizer recently declared a quarterly dividend of $0.43 per share, with a current yield of 7.0%, reflecting a payout ratio of 91.49%.

Itau Unibanco Holding S.A. lessened its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 99.7% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 1,720 shares of the biopharmaceutical company's stock after selling 500,000 shares during the quarter. Itau Unibanco Holding S.A.'s holdings in Pfizer were worth $44,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in PFE. Brighton Jones LLC boosted its stake in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after buying an additional 618,117 shares during the period. Revolve Wealth Partners LLC increased its holdings in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after acquiring an additional 2,087 shares during the last quarter. Voleon Capital Management LP purchased a new position in shares of Pfizer in the 4th quarter valued at about $2,120,000. Kapitalo Investimentos Ltda purchased a new position in shares of Pfizer in the 4th quarter valued at about $89,000. Finally, Triumph Capital Management increased its holdings in shares of Pfizer by 20.0% in the 4th quarter. Triumph Capital Management now owns 10,283 shares of the biopharmaceutical company's stock valued at $273,000 after acquiring an additional 1,717 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on PFE shares. Morgan Stanley increased their price objective on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Berenberg Bank dropped their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. Jefferies Financial Group increased their price objective on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a report on Wednesday, May 21st. Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Finally, Bank of America boosted their target price on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $28.12.

Pfizer Stock Performance

NYSE PFE opened at $24.60 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The business's 50-day moving average price is $24.78 and its 200 day moving average price is $24.39. The firm has a market cap of $139.86 billion, a P/E ratio of 13.09, a P/E/G ratio of 0.89 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter last year, the company posted $0.60 earnings per share. The business's revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.0%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio is currently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.